Updates in the Treatment of HR+ Breast Cancer - Episode 9

Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

, , ,

A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.

EP. 1: Expert Insights on Biomarker Testing in Early-Stage Breast Cancer
EP. 2: Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer
EP. 3: Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer
EP. 4: Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer
EP. 5: Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA
EP. 6: Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer
EP. 7: Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer
EP. 8: Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant
Now Viewing
EP. 9: Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer
EP. 10: ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06
EP. 11: Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer
EP. 12: Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

Video content above is prompted by the following:

  • What are the other options for advanced HR+ disease(PI3K/AKT/mTOR inhibitors)?
    • When and how are these being used? Are there any AEs of concern? How do you manage?
    • ADCs